“…These and other blood-stage candidates (reviewed in [36]) have been shown to be highly immunogenic and protective against both homologous and heterologous challenge with different parasite strains (Table 1), although the persistence of high levels of parasitemia after immunization raises some concerns about their biosafety. Further GAP strategies and recent vaccine candidates intend to improve the attenuated phenotype of whole blood-stage parasites, boost T and B cell responses, and induce cross-stage, cross-species and long-lasting immunity [56,57].…”